Biotech Companies Continue IPO Hot Streak, but for How Long?

"With public investors eager to tap into biotech innovation, startups this year have streamed onto Nasdaq despite market volatility that would have slowed offerings previously. And the access to the public markets that biotechs are enjoying is creating a virtuous cycle, investors say. Their ability to go public early increases their appeal to crossover investors, and wellfunded biotechs are strong candidates to go public."

Read the article (subscription required)

Related Contacts
Div Gupta  Partner New York
Related Practices & Industries

Capital Markets  Public Companies  Life Sciences